PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference ABL - 008 - PCT	FOR FURTHER see Notification of (Form PCT/ISA/2	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.		
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)		
PCT/BE 03/00190	07/11/2003	08/11/2002		
Applicant ABLYNX N.V.				
according to Article 18. A copy is being tra		nority and is transmitted to the applicant		
	a copy of each prior art document cited in this	report.		
Basis of the report With regard to the language, the language in which it was filed, unl	international search was carried out on the bas ess otherwise indicated under this item.	sis of the international application in the		
the international search w Authority (Rule 23.1(b)).	ras carried out on the basis of a translation of t	he international application furnished to this		
b. With regard to any nucleotide an was carried out on the basis of the contained in the internation filed together with the intext of turnished subsequently to the statement that the subsequent application a	e sequence listing: onal application in written form. rnational application in computer readable form this Authority in written form. this Authority in computer readble form. esequently furnished written sequence listing designed in the sequence of	•		
2. X Certain claims were fou	nd unsearchable (See Box I).			
3. X Unity of invention is lac	king (see Box II).			
	hed by this Authority to read as follows: .GAINST IMMINOGLOBULIN E AND	USE THEREOF FOR THE		
5. With regard to the abstract, X the text is approved as substract the text has been establish within one month from the	omitted by the applicant. ned, according to Rule 38.2(b), by this Authorit date of mailing of this international search rep	y as it appears in Box III. The applicant may, ort, submit comments to this Authority.		
6. The figure of the drawings to be publi as suggested by the applicant failed because this figure better	cant.	None of the figures.		

International Application No PCT/BE 03/00190

Relevant to claim No.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/42 C07K16/24 C07K16/30 C07K16/12 C07K16/10
C07K16/40 C07K16/28 C12N15/13 A61K39/395 A61P11/06
A61P35/00 A61P31/06 A61P31/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Category °

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Citation of document, with indication, where appropriate, of the relevant passages

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, GENSEQ, EMBL

X DZ Y X D3 Y	US 2002/054878 A1 (LOWE JOHN 9 May 2002 (2002-05-09) claims 8-31 examples 2-4 WO 91/02078 A (PEPTIDE TECHNOUS 21 February 1991 (1991-02-21) page 4, lines 15-24 her documents are listed in the continuation of box C.		34,58-63 1,6-24, 33,34 1-24,33, 34,58-63 11-25, 59,60,63 11-25, 58,61
"A" docume consid "E" earlier of filing of the which citation "O" docume other r	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but nan the priority date claimed	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the c cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the c cannot be considered to involve an involve an inventive step when the do cannot be considered to involve an involve an involve an involve an involve an inventive combined with one or more ments, such combination being obvious in the art. "&" document member of the same patent.	the application but cory underlying the laimed invention be considered to current is taken alone laimed invention ventive step when the re other such docu-us to a person skilled

6

NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016

ALCONADA RODRIGUEZ

International Application No.
PCT/BE 03/00190

		C1/BE 03	/ 00130	
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
zategory ³	Organori or document, warr moreauori, where appropriate, or the relevant passages			
/ D4	MUYLDERMANS S: "SINGLE DOMAIN CAMEL ANTIBODIES: CURRENT STATUS" REVIEWS IN MOLECULAR BIOTECHNOLOGY, ELSEVIER, AMSTERDAM,, NL, vol. 74, no. 4, June 2001 (2001-06), pages 277-302, XP001057480 ISSN: 1389-0352 table 1		1-24,33, 34,58-63	
	VALLE E ET AL: "Infliximab" EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB,		11-25	
D5.	vol. 2, June 2001 (2001–06), pages 1015–1025, XP002965315 ISSN: 1465–6566 the whole document		·	
			-	
			,	
			·	
i		:		
ļ				

6

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-24 and 58-63 (in part) and 33, 34 (complete)

A camelidae VHH single domain antibody directed against IgE, in particular, the polypeptides represented by any of SEQ ID NO:1-11; a nucleic acid encoding for said VHH, use of the antibody for the preparation of a medicament for treating or alleviating disorders relating to inflammatory regions, a method for delivering an anti-target compound to a subject by administering the anti-IgE VHH antibodies, the anti-IgE antibodies for use in the treatment of an allergic response, the camelidae VHH anti-IgE which is humanised and the camelidae VHH anti-IgE in a composition togehter with a pharmaceutical carrier.

2. claims: 11-24 and 58-63 (in part) and 25-26 (complete)

As invention 1 but relating to an anti-TNF-alpha camelidae VHH antibody (SEQ ID NO:12-14) and the uses thereof for the treatment of inflammation.

3. claims: 11-24 a

As inventio antibody an cancer.

Marolien, Invest 2. 7 (complete)

nti-CEA camelidae VHH he treatment of colon

4. claims: 11-24 ar

3, 29, 40-44 (complete)

As invention 1 but relating to a single domain antibody directed an internalising cellular receptor, in particular the anti-EGF recetpr camelidae VHH antibody (SEQ ID NO:23-44) and the uses thereof for the treatment of head, neck, lung and colon cancer.

5. claims: 11-24, 39 and 58-63 (in part) and 30 (complete)

As invention 1 but relating to single domain antibodies against an antigen of Helicobacter pylori and the uses thereof for the treatment of indigestion and gastritis.

6. claims: 11-24, 39 and 58-63 (in part) and 31 (complete)

As invention 1 but relating to single domain antibodies against an antigen of Mycobacterium tuberculosis and the uses thereof for the treatment of tuberculosis.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. claims: 11-24, 39 and 58-63 (in part) and 32 (complete)

As invention 1 but relating to single domain antibodies against an antigen of the influenza virus and the uses thereof for the treatment of flu.

8. claims: 11-24 and 58-63 (in part) and 35-36 (complete)

As invention 1 but relating to an anti-MMP camelidae VHH antibody (SEQ ID NO:15-22) and the uses thereof for the treatment of cancer.

9. claims: 11-24 and 58-63 (in part) and 37-38 (complete)

As invention 1 but relating to an anti-IFN-gamma camelidae VHH antibody (SEQ ID NO:45-70) and the uses thereof for the treatment of cancer, transplant rejection and an auto immune disorder.

10. claims: 11-24 and 58-63 (in part) and 45, 46 (complete)

As invention 1 but relating to an anti-PDK camelidae VHH antibody and the uses thereof for the treatment of cancer.

11. claims: 11-24 and 58-63 (in part) and 47, 48 (complete)

As invention 1 but relating to single domain antibodies against GSK1, Bad, caspase and Forkhead and the uses thereof for the treatment of cancer.

Information on patent family members

International Application No
PCT/BE 03/00190

Patent document					
cited in search report		Publication date		Patent family member(s)	Publication date
EP 0589840	Α	30-03-1994	AT	264388 T	15-04-2004
21 0303010	•	00 00 100.	AU	675449 B2	06-02-1997
			AU	4748893 A	31-03-1994
			CA	2106719 A1	25-03-1994
			CN	1428352 A	09-07-2003
			CN	1088986 A ,B	06-07-1994
			DE	69333484 D1	19-05-2004
•			EP	0589840 A1	30-03-1994
			FI	934145 A	25-03-1994
			FΙ	20040696 A	19-05-2004
			JP	6225788 A	16-08-1994
			MX	9305920 A1	31-05-1994
				933394 A	25-03-1994
			NO NZ		27-04-1995
			NZ	248743 A	
			SG	49856 A1	19-03-2002
			ZA	9307033 A	11-08-1994
			US	6066718 A	23-05-2000
			US	5958708 A	28-09-1999
			US	6072035 A	06-06-2000
US 2002054878	A1	09-05-2002	US	6290957 B1	18-09-2001
03 2002034070	***	03 00 2002	ÜS	5994511 A	30-11-1999
			US	2003149244 A1	07-08-2003
			AT	253116 T	15-11-2003
			ΑÚ	741115 B2	22-11-2001
			AU	8270198 A	25-01-1999
		* *	CA	2295540 A1	14-01-1999
			CN	1268176 T	27-09-2000
			DE	69819332 D1	04-12-2003
			DK	996728 T3	23-02-2004
			EP	0996728 A2	03-05-2000
			HU	0002474 A2	28-10-2000
					02-04-2002
			מו	2002610211 1	
			JP	2002510211 T	
			NO	996551 A	01-03-2000
			NO NZ	996551 A 501842 A	01-03-2000 01-02-2002
			NO NZ PL	996551 A 501842 A 338030 A1	01-03-2000 01-02-2002 25-09-2000
			NO NZ PL PT	996551 A 501842 A 338030 A1 996728 T	01-03-2000 01-02-2002 25-09-2000 31-03-2004
			NO NZ PL PT SK	996551 A 501842 A 338030 A1 996728 T 187599 A3	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001
			NO NZ PL PT SK TR	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000
			NO NZ PL PT SK TR WO	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999
			NO NZ PL PT SK TR	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000
			NO NZ PL PT SK TR WO ZA	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078		21-02-1991	NO NZ PL PT SK TR WO ZA AU AU	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU AU WO	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU AU WO EP	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE DE	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE DK	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2 486526 T3	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE DK JP	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2 486526 T3 3443119 B2	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE DK JP JP	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2 486526 T3 3443119 B2 2003096096 A	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE DE JP JP JP	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 D1 69027121 T2 486526 T3 3443119 B2 2003096096 A 2003231699 A	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
WO 9102078	A	21-02-1991	NO NZ PL SK WO ZA AU WO EP DE DE JP JP US	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2 486526 T3 3443119 B2 2003096096 A 2003231699 A 2003162948 A1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL PT SK TR WO ZA AU WO EP CA DE DE JP JP JP	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 D1 69027121 T2 486526 T3 3443119 B2 2003096096 A 2003231699 A	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL SK WO ZA AU WO EP DE DE JP JP US	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2 486526 T3 3443119 B2 2003096096 A 2003231699 A 2003162948 A1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999
 WO 9102078	A	21-02-1991	NO NZ PL SK WO ZA AU WO EP DE JP JP US US	996551 A 501842 A 338030 A1 996728 T 187599 A3 200000206 T2 9901556 A2 9805500 A 640400 B2 6145490 A 9102078 A1 0486526 A1 2064915 A1 69027121 D1 69027121 T2 486526 T3 3443119 B2 2003096096 A 2003231699 A 2003162948 A1 2003232970 A1	01-03-2000 01-02-2002 25-09-2000 31-03-2004 06-08-2001 21-07-2000 14-01-1999 24-12-1999

information on patent family members

International Application No
PCT/BE 03/00190

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9102078	Α	US	2003216552 A1	20-11-2003
		US	2004002589 A1	01-01-2004
		US	2003208047 A1	06-11-2003
		US	5644034 A	01-07-1997
		US	2003171554 A1	11-09-2003
		US	2003171555 A1	11-09-2003
		US	2004002590 A1	01-01-2004
		US	2004092721 A1	13-05-2004
		US	2003225254 A1	04-12-2003
		US	6416757 B1	09-07-2002
		US	2003232971 A1	18-12-2003
		US	6593458 B1	15-07-2003
		US	2001018507 A1	30-08-2001
		US	2001023287 A1	20-09-2001
		US	2001018508 A1	30-08-2001

International application No. PCT/BE 03/00190

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 11-18, 25-39 and 49-57 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the
alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-24 and 58-63 (in part) and 25-26, 33, 34 (complete)
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 11-18, 25-39 and 49-57 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.